aTyr Pharma (aTyr Pharma) Total Liabilities : $30.18 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is aTyr Pharma Total Liabilities?

aTyr Pharma's Total Liabilities for the quarter that ended in Dec. 2023 was $30.18 Mil.

aTyr Pharma's quarterly Total Liabilities increased from Jun. 2023 ($26.70 Mil) to Sep. 2023 ($26.87 Mil) and increased from Sep. 2023 ($26.87 Mil) to Dec. 2023 ($30.18 Mil).

aTyr Pharma's annual Total Liabilities increased from Dec. 2021 ($6.41 Mil) to Dec. 2022 ($24.50 Mil) and increased from Dec. 2022 ($24.50 Mil) to Dec. 2023 ($30.18 Mil).

aTyr Pharma Total Liabilities Historical Data

The historical data trend for aTyr Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

aTyr Pharma Total Liabilities Chart

aTyr Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

15.16

7.24

6.41

24.50

30.18

aTyr Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															24.50	27.14	26.70	26.87	30.18

aTyr Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

aTyr Pharma's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	16.416	+	(13.767	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	30.18

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	120.653	-	90.47
	=	30.18

aTyr Pharma's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	16.416	+	(13.767	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	30.18

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	120.653	-	90.47
	=	30.18

aTyr Pharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of aTyr Pharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

aTyr Pharma (aTyr Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » aTyr Pharma Inc (NAS:LIFE) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

471A:Germany

Address

10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121

Website

https://www.atyrpharma.com

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Executives

Sanjay Shukla	officer: Chief Medical Officer	C/O ATYR PHARMA, INC., 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO CA 92121
Paul Schimmel	director	88 SIDNEY ST, CAMBRIDGE MA 02139
Jill Marie Broadfoot	officer: Chief Financial Officer	3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Sara Zaknoen	director	C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
John K Clarke	director	C/O CARDINAL HEALTH PARTNERS, 221 NASSAU STREET, PRINCETON NJ 08542
Nancy Krueger	officer: See Remarks	C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Svetlana Lucas	director	3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Jane A Gross	director	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
John Mendlein	director, officer: CEO and Executive Chairman
Ecor1 Capital Fund Qualified, L.p.	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ashraf Amanullah	officer: Vice President, Manufacturing	C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
John T Blake	officer: Vice President, Finance	C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342
Timothy P Coughlin	director	339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075
Jeffrey S. Hatfield	director	11080 ROSELLE STREET, SAN DIEGO CA 92121
David John King	officer: See Remarks	3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121